VPRIV Approval History
FDA Approved: Yes (First approved February 26, 2010)
Brand name: VPRIV
Generic name: velaglucerase alfa
Dosage form: for Injection
Company: Shire plc
Treatment for: Gaucher Disease
VPRIV (velaglucerase alfa) is a hydrolytic lysosomal glucocerebroside-specific enzyme indicated for long-term enzyme replacement therapy for pediatric and adult patients with Type 1 Gaucher disease.
Development History and FDA Approval Process for VPRIV
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.